Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160

Tetsu Yano, Sinisa Radulovic, Yutaka Osuga, Koji Kugu, Hiroyuki Yoshikawa, Yuji Taketani, Andrew V. Schally

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


In this study, we investigated the effects of somatostatin analog RC-160 on the growth of the OV-1063 human epithelial ovarian cancer cell line in vitro. RC-160 inhibited cell proliferation, as measured by cell number, and [3H]thymidine incorporation into DNA at 10-9-10-5 M. In OV-1063 cells, 125I-labeled RC-160 was bound to one class of specific, saturable binding sites with high affinity (K(d) = 0.2 ± 0.03 nM) and low capacity (5,500 binding sites per cell).125I-labeled RC-160 could be displaced by unlabeled RC-160. Ligand binding was dependent on time and temperature. Receptor internalization assay showed that the ligand-receptor complex was internalized at 37°, which indicates the presence of biologically active somatostatin receptors on OV-1063 cells. These results suggest that somatostatin analog RC-160 can suppress the growth of OV-1063 human epithelial ovarian cancer cells by a direct action and that the inhibitory effect of somatostatin analog is mediated through the high-affinity somatostatin receptors. Copyright (C) 2000 S. Karger AG, Basel.

Original languageEnglish (US)
Pages (from-to)45-49
Number of pages5
Issue numberSUPPL. 1
StatePublished - 2000
Externally publishedYes


  • Ovarian cancer
  • Somatostatin
  • Somatostatin analog
  • Somatostatin receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Inhibition of human epithelial ovarian cancer cell growth in vitro by somatostatin analog RC-160'. Together they form a unique fingerprint.

Cite this